About this trial
The EQUIP Study is testing whether high-risk human papillomavirus (hrHPV), the virus that causes most cervical cancers, can be accurately detected from menstrual blood collected at home. People who have been referred for colposcopy after an abnormal Pap or hrHPV test will use the Q-Pad Kit during their period to collect menstrual samples on a special menstrual pad and mail them to a central laboratory for hrHPV testing.
The same participants will have a standard cervical sample collected for routine hrHPV testing and will undergo colposcopy as part of their usual care. By comparing hrHPV results from menstrual samples with results from cervical samples and biopsy findings, the study will evaluate how well the Q-Pad hrHPV Test System detects cervical precancer and will also assess how easy and acceptable it is for participants to use this at-home collection method.
Eligibility criteria
Qualifiers
You are 25 years old or older and have an intact cervix.
You were referred for a colposcopy after an abnormal Pap or HPV screen.
Your periods come regularly-about every 21-35 days.
You own a smartphone, have an email address, and can read the Qvin app instructions in English.
Disqualifiers
You are pregnant or think you might be.
You are unwilling or unable to use the two Q-Pads and mail them back (mailing costs are covered).
You had treatment for cervical pre-cancer (CIN2+)-such as LEEP, cone, or ablation-within the last 12 months.
You have already joined this study or are in another cervical-screening / HPV study right now.
Trial design
Treatments tested in this trial
- Q-Pad hrHPV Test System
Treatment groups
Locations
4Sponsors and collaborators
Qurasense
Lead sponsor